Metformin + ADT in treatment of advanced prostate cancer

Yet another study, just published in the Journal of Urology, has indicated a clear association between the use of metformin along with androgen deprivation therapy (ADT) in the treatment of advanced forms of prostate cancer.

A potential downside to metformin in the treatment of men with diabetes

There have been suggestions for some time (but no confirmation yet from large scale clinical trials) that treatment with the antidiabetic agent metformin may be beneficial in the management of at least some forms of prostate cancer. However, …

Metformin + BI2536 may have significant activity in mCRPC

According to an new article in the Journal of Biological Chemistry, the combination of metformin with a polo-like kinase 1 (Plk1) inhibitor known currently as BI2536 appears to be able to suppress the spread of prostate cancer that resists all other available treatments.

The value of metformin in management of prostate cancer: the debate continues

Available data offer both positive and negative evidence from observational studies regarding the value of metformin in the management of men newly diagnosed with prostate cancer.

The potential of metformin in prostate cancer treatment: an update

We have previously commented (more than once) on the perception that metformin may have some value in the management of prostate cancer. A recently reported (albeit small), prospective Swiss study, has added to our knowledge in this regard.

Potential of metformin in management of recurrent/progressive prostate cancer

A newly published, retrospective, epidemiological study has looked at the potential role of metformin the the management of prostate cancer in > 350 men already diagnosed and being treated for diabetes in the Shared Equal Access Regional Cancer Hospital (SEARCH) database.

Can metformin extend survival of prostate cancer patients with (or without) diabetes?

A retrospective analysis of data from  > 3,800 Canadian men has suggested that diabetic men who also had prostate cancer and were being treated with a commonly used, generic drug called metformin have a reduced risk for death from prostate cancer.

Neoadjuvant metformin in localized prostate cancer: not ready for prime time yet

A paper presented on Saturday at the annual meeting of the American Association for Cancer Research in Chicago has suggested the possibility of better outcomes after radical prostatectomy among men taking the diabetes drug metformin before their surgery … but the data are from a very small study.

Metformin in the management of ADT-related side effects and morbidities

A newly published article in BJU International offers data from a small, randomized, pilot study of the use of metformin and lifestyle changes in the prevention of cardiovascular morbidity and androgen deprivation therapy (ADT)-related metabolic syndrome.

Diabetes and risk for prostate cancer

There have long been suggestions that men already diagnosed with and receiving treatment for diabetes are at lower risk for a subsequent diagnosis of prostate cancer than non-diabetics. However, a very large, new, epidemiological analysis seems to suggest strongly that this may not be the case at all.

Data from the TAXOMET trial also presented at ASCO

Data from a small, Phase II, French trial known as the TAXOMET trial were also presented yesterday at the ASCO meeting.

Howard Wolinsky’s continuing patient journey

To quote Howard himself, “Not much on PC, but FYI.” But on the other hand, it is very much about the sometimes challenging aspects of “being a patient” — prostate cancer included.

Statins in the prevention and management of prostate cancer: an update

A recent review article in the journal Nature Reviews: Urology has concluded that, while we are learning a lot more about the potential role(s) of statins in the prevention and management of prostate cancer, we still have no definitive evidence of their value.

PORTOS: a gene signature that predicts salvage radiation success

Salvage radiation is curative in roughly half of all cases. There are many factors that contribute to an unfavorable prognosis, including waiting too long, high PSA and rapid PSA doubling time, adverse post-surgery pathology (stage, Gleason score, positive margins), and high Decipher or CAPRA-S scores. But,

What’s being presented at the AUA in May: Part VII

A total of 44 presentations and posters address prostate cancer-specific topics under the general heading of “epidemiology and natural history” in three sessions at the annual meeting of the American Urological Association this year.